Drugs / GZR101
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06556641 | Dec 2022 → Feb 2023 | — | Gan and Lee Pharmaceuticals, USA | Completed | No outcome recorded |
| Phase 1 | NCT06548932 | Jun 2022 → Feb 2023 | — | Gan and Lee Pharmaceuticals, USA | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06558708 | Jun → Dec 2024 overdue | type 2 diabetes mellitus | Gan and Lee Pharmaceuticals, USA | Recruiting | No outcome recorded |
| Phase 2 | NCT06199505 | Nov 2023 → Jun 2024 | type 2 diabetes mellitus | Gan and Lee Pharmaceuticals, USA | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GZR101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06556641 ↗ |
| Route | Subcutaneous | “GZR101 injection s.c., once daily, treat-to-target dose” NCT06199505 ↗ |